Synonyms: compound 12 [PMID 25616005] [2]
Compound class:
Synthetic organic
Comment: CPP-115 is a vigabatrin analogue with improved tolerability compared to the parent compound [1].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
The hydrochloride salt of CPP-115 (PubChem CID 71252718) has been granted orphan drug designation by the EMA for the treatment of West syndrome, an epileptic disorder of young children which causes developmental problems. West syndrome is a long-term debilitating disease which may be life threatening as it can lead to severe damage to motor and cognitive functions. CPP-115 may have additional therapeutic applications for treating other neurological disorders, including drug addiction [4]. A single Phase 1 clinical trial has assessed CPP-115 as a treatment for cocaine addiction [3], but development has not progressed further. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
CPP-115 inhibits GABA aminotransferase [2,5] activity, which is responsible for the catabolic degradation of the principal inhibitory neurotransmitter GABA. Inhibition of GABA aminotransferase leads to increased concentrations of GABA in the brain and is able to terminate seizures [1] which are the result of pathophysiologically low GABA levels. |